Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.41 |
| ▸ | CCNC | P24863 | 10/20 | 0.40 |
| ▸ | CDK8 | P49336 | 10/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783391 | 0.84 | CYP11B2 (0.45) | GPR55KCNJ1CYP11B2MEN1LMNA | |
| SCHEMBL783451 | 0.80 | GPR55 (0.40) | GPR55KCNJ1CYP11B2 | |
| SCHEMBL782504 | 0.80 | CYP11B2 (0.47) | GPR55CCNCCDK8KCNJ1CYP11B2 | |
| SCHEMBL782992 | 0.79 | GPR55 (0.44) | GPR55KCNJ1CYP11B2MEN1PKM | |
| SCHEMBL782551 | 0.79 | CYP11B2 (0.40) | GPR55KCNJ1CYP11B2 | |
| SCHEMBL744470 | 0.79 | GPR55 (0.44) | GPR55KCNJ1CYP11B2 | |
| SCHEMBL782297 | 0.77 | GPR55 (0.42) | GPR55KCNJ1CYP11B2 | |
| SCHEMBL783338 | 0.76 | KCNJ1 (0.45) | GPR55KCNJ1CYP11B2 | |
| SCHEMBL782662 | 0.76 | KCNJ1 (0.42) | GPR55KCNJ1CYP11B2 | |
| SCHEMBL782951 | 0.76 | CYP19A1 (0.55) | GPR55CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430018-B1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| EP-2430018-B1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| EP-2430018-A2 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | Novartis AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130773-A2 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | GPR55 852/4885CCNC 4180/4885CDK8 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.